Correlation between CD44 expression on histopathological grading, metastasis, survival overall (SO) and disease free survival (DFS) on women breast cancer
Ahmad Syaifudin(1*), Septiman Septiman(2), Indra Indra(3), Prihantono Prihantono(4)
(1) Department of Surgery, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia
(2) Division of Oncology Surgery, Department of Surgery, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia
(3) Division of Oncology Surgery, Department of Surgery, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia
(4) Division of Oncology Surgery, Department of Surgery, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia
(*) Corresponding Author
Abstract
Breast cancer is one of the health problems in the world. In Indonesia, it washighest prevalence of cancerin 2018. CD44, a non-kinase transmembrane glycoprotein, plays an important role in cancer development and progression.It isresponsible for mediating of the adhesion between adjacent cells andalsobetween cells and the extracellular matrix. The aim of study was to investigatethe relationship between the CD44 expressionand histopathological grading, metastasis, overall survival (OS) as well as disease free survival (DFS)in breast cancer patients.Thiswas a retrospective cross sectional studyusing data on medical records of breast cancer cases at Dr. Wahidin Sudirohusodo General Hospital, Makasarfrom 2016 to 2018. Examination of CD44 expression were performed from paraffin block samples.Data of the CD44 expression and medical records obtained were then presented in tables and statistically analyzed using chi-squared and Kaplan–Meier survival analysis.No significantly relationship between the CD44 expression and histopathological grading was reported (p>0.05). However, significantly relationship between the CD44 expression and metastasis war reported (p<0.01). Patients with metastasis havinghigh CD44 expression was significantly higher (90%) than those patients without metastasis (60%) (p<0.01). No significantly relationship between the CD44 expression and OS or DFS was reported (p>0.05). In conclusion, there isrelationship between CD44 expression and metastasis in the breast cancer patients. However, there is norelationship between CD44 expression and histopathological grading, OS as well as DFS.
Keywords
Full Text:
PDFReferences
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018 Nov; 68(6):394-424.
- Balitbang Kemenkes RI. Riset kesehatan dasar; RISKESDAS. Jakarta: Balitbang Kemenkes RI. 2013; 2013:110-9.
- Hamdani W. Analisis Kadar Her-2 mRNA CTC darah pada kemoterapineoadjuvant pasien KPD stad III, tipe Her-2 vs Non Her-2 dan analisis kadar Her-2 mRNA pada kemoterapi adjuvant sebagai predictor rekuren. [Dissertation]. Makasar: Universitas Hasanuddin; 2014.
- Ramli M. Update breast cancer management diagnostic and treatment. Majalah Kedokteran Andalas 2015; 24(38):28-53.
- Agustina J, Sinulingga D, Susana E, Andinata B, Ramadhan R, Kadir A. Epidemiology of female breast cancer in West Jakarta, Indonesia. J Global Oncol 2018; 4(2). https://doi.org/10.1200/jgo.18.63300
- Kotowicz B, Fuksiewicz M, Gmyrek JJ, Bidzinski M, Kowalska M. The assessment of the prognostic value of tumor markersand cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer,particularly with early stage of the disease. Tumor Biol 2016; 37:1271–8. https://doi.org/10.1007/s13277-015-3914-0
- Jing JX, Wang Y, Xu AQ, San T, Tian BG, Du LL, et al. Tumormarkers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer. Asian Pasific J Cancer Prev 2014; 15(23):10267-72. https://doi.org/10/7314/APJCP.2014.15.23.10267
- Kabel AM. Tumor markers of breast cancer: new prospectives. J Oncol Sci 2017; 3(1):5-11. https://doi.org/10.1016/j.jons.2017.01.001
- McFarlane S, Coulter JA, Tibbits P, O’Grady A, McFarlane C, Montgomery N, et al. CD44 increases the efficiency of distant metastasis of breast cancer. Oncotarget 2015; 6(13):11465-76. https://doi.org/10.18632/oncotarget.3410
- Kong Y, Lyu N, Wu J, Tang H, Xie Z, Yang L, et al. Breast cancer stem cell markers CD44 and ALDH1A1 in serum: Distribution and prognostic value in patients with primary breast cancer. J Cancer 2018; 9(20):3728-35. https://doi.org/10.7150/jca.28032
- Xu H, Tian Y, Yuan X, Liu Y, Wu H, Liu Q, et al. Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis. Onco Targets Ther 2016; 9:431-44. htpps://doi.org/10.2147/OTT.S97192
- Farida A, Wresnindyatsih, Yuliantini V. Correlation CD24 and CD44 expression against aggressiveness breast cancer. JPhys Conf Ser 2019; 1246(1):012012). https://doi.org/10.1088/1742-6596/1246/1/012012
- Jang MH, Kang HJ, Jang KS, Paik SS, Kim WS. Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer. Oncol Lett 2016; 12(4): 2728–33. https://doi.org/10.3892/ol.2016.4987
- Mansoori M, Roudi R, Abbasi A, Abolhasani M, Rad IA, Shariftabrizi A, et al. High GD2 expression defines breast cancer cells with enhanced invasiveness. Exp Mol Pathol 2019; 109:25-35. https://doi.org/10.1016/j.yexmp.2019.05.001
- McFarlane S, Coulter JA, Tibbits P, O’Grady A, McFarlane C, Montgomery N, Hill A, McCarthy HO, Young LS, Kay EW, Isacke CM. CD44 increases the efficiency of distant metastasis of breast cancer. Oncotarget 2015; 6(13):11465-76. https://doi.org/10.18632/oncotarget.3410
- Qiao GL, Song LN, Deng ZF, Chen Y, Ma LJ. Prognostic value of CD44v6 expression in breast cancer: a meta-analysis. Onco Targets Ther 2018; 11:5451-7. https://doi.org/10.2147/OTT.S156101
DOI: https://doi.org/10.19106/JMedSci005203202006
Article Metrics
Abstract views : 1380 | views : 1529Copyright (c) 2020 Ahmad Syaifudin, Septiman Septiman, Indra Indra, Prihantono Prihantono
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.